Personalized Medicine in Oncology

Nyhet

Precision Oncology and Transformative Technologies

Inbunden, Engelska, 2026

2 389 kr

Kommande

This book covers the field of precision oncology and is aligned with the targeted therapy drug development paradigm. Chapters present the relevance of immunotherapies as important and pivotal treatment strategies for cancer. The book outlines how Immune checkpoint inhibitors, CAR T cell therapies, antibody drug conjugates and bispecific antibodies evolved through the conduct of clinical trials and the resulting data to become critical components of the oncologist’s armamentarium. The mechanism of each class is described in detail and how each has advantages and limitations concerning existing standards of care, demonstrating that they complement and contrast with each other; resistance mechanisms are also discussed. This book sufficiently fills a gap by coalescing these studies into a thorough, yet clear compendium of these therapies. It describes the prognostic and predictive significance of each drug, biomarkers for determining their therapeutic potential, along with the assays (e.g., IHC) that evaluate them. Personalized Medicine in Oncology is a valuable resource for oncologists and clinicians as well as graduate medical students, cancer nurse practitioners, pharmacists, and clinicians in other related therapeutic areas of interest.

Produktinformation

Utgivningsdatum2026-02-16
Mått155 x 235 x undefined mm
FormatInbunden
SpråkEngelska
Antal sidor342
FörlagSpringer Nature Switzerland AG
ISBN9783032144362

Tillhör följande kategorier

Onkologi inom Medicin

Priya HaysHays Documentation SpecialistsSan Mateo, CA USA Priya Hays, M.S., Ph.D. is an accomplished science writer, having written and published five books as well as having authored over thirty publications in journals as varied as the Bulletin of Science, Technology and Society, L’Esprit Createur, Interdisciplinary Literary Studies, Genetics in Medicine, European Journal of Medical Research and Discover Oncology focusing on personalized medicine and precision oncology. She served as Guest Editor for a volume on cancer immunotherapies in the Cancer Treatment and Research series and wrote the second edition of her book on personalized medicine Advancing Healthcare Through Personalized Medicine, both published by Springer Nature. Her sixth book is a compilation of her published and conference papers entitled “A Dialectical Mind: Essays in Literary Studies, Science and Medicine” published by Eliva Press. She is a member of the American Association of Cancer Research, American Society for Clinical Oncology, Society for Immunotherapy of Cancer, the American College of Genetics and Genomics and the American Association of Immunologists and is ranked in the top 0.5% of all scholars worldwide by ScholarGPS. Her work has been featured in The ASCO Post and Blood Cancers Today. She completed her postdoctoral research fellowship in the Division of Hematology/Oncology, Department of Medicine, at Dartmouth Medical School. She has an A.B. with Honors from Dartmouth College in Biochemistry and Comparative Literature, an M.S. in Genetics from the University of California, Davis, and a Ph.D. in Literature from the University of California, San Diego.

Introduction: The Development of Precision Medicine.- Part I.-Targeted Therapies Solid Tumors.-Targeted Therapies Hematological malignancies .-Cancer Immunotherapies Parts 1 and 2.-Checkpoint Blockade.-Cellular Therapies.-Bispecific Antibodies.-Antibody Drug Conjugates.-Personalized Cancer Vaccines.-Combination Therapies.-Immunogenomics.-Part II.-Economic Evaluations of Precision Oncology.-Ethical Issues, Health Policy and Law .-Artificial Intelligence and Big Data in Oncology.-Public Health and Global Healthcare in Personalized Cancer.-Regulatory Frameworks.-Health Disparities.-Conclusion: Neoadjuvant and Adjuvant Care Settings.